Cheree H. Johnson
Known title: SVP,Chief Legal Ofcr, GC &SecCIK: 0001840114
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Transaction History
| SPXC | ▼ Sell | Tax Withholding | 396 | $66K | 7/1/2025 | View on chart |
| SPXC | ▲ Buy | Grant | 3,414 | — | 3/3/2025 | View on chart |
| SPXC | ▲ Buy | Grant | 4,129 | — | 7/1/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 291 | $0 | 1/13/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 65,359 | $0 | 11/16/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 110 | $0 | 10/14/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 85 | $0 | 7/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 63 | $0 | 4/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 6,098 | $0 | 3/4/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 18,762 | $0 | 3/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
SPXC receives analyst coverage and growth focus
Recent analyst notes emphasize SPX Technologies' growth profile, citing its market position and revenue trends. Oppenheimer kept an Outperform rating but adjusted its price target to $270, reflecting a more modest outlook. A separate piece highlighted the compound return of a $100 investment over 15 years, underscoring the stock’s long‑term performance while it trades near the lower end of its 52‑week range.
SPXC receives analyst coverage and growth focus. Recent analyst notes emphasize SPX Technologies' growth profile, citing its market position and revenue trends. Oppenheimer kept an Outperform rating but adjusted its price target to $270, reflecting a more modest outlook. A separate piece highlighted the compound return of a $100 investment over 15 years, underscoring the stock’s long‑term performance while it trades near the lower end of its 52‑week range.